Ascendis Pharma A (ASND) Non-Current Receivables (2016 - 2025)
Historic Non-Current Receivables for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $17.0 million.
- Ascendis Pharma A's Non-Current Receivables rose 6926.93% to $17.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.0 million, marking a year-over-year increase of 6926.93%. This contributed to the annual value of $16.5 million for FY2025, which is 6431.88% up from last year.
- Latest data reveals that Ascendis Pharma A reported Non-Current Receivables of $17.0 million as of Q4 2025, which was up 6926.93% from $11.2 million recorded in Q3 2025.
- Ascendis Pharma A's 5-year Non-Current Receivables high stood at $32.0 million for Q2 2024, and its period low was $8.7 million during Q1 2021.
- Over the past 5 years, Ascendis Pharma A's median Non-Current Receivables value was $16.4 million (recorded in 2022), while the average stood at $17.0 million.
- Per our database at Business Quant, Ascendis Pharma A's Non-Current Receivables surged by 35338.98% in 2021 and then crashed by 7156.37% in 2025.
- Quarter analysis of 5 years shows Ascendis Pharma A's Non-Current Receivables stood at $23.0 million in 2021, then tumbled by 43.04% to $13.1 million in 2022, then soared by 56.93% to $20.5 million in 2023, then plummeted by 51.19% to $10.0 million in 2024, then soared by 69.27% to $17.0 million in 2025.
- Its Non-Current Receivables stands at $17.0 million for Q4 2025, versus $11.2 million for Q3 2025 and $9.1 million for Q2 2025.